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The paracaspase Malt1 is a central regulator of anti-
gen receptor signaling that is frequently mutated in
human lymphoma. As a scaffold, it assembles pro-
tein complexes for NF-kB activation, and its proteo-
lytic domain cleaves negative NF-kB regulators for
signal enforcement. Still, the physiological functions
of Malt1-protease are unknown. We demonstrate
that targeted Malt1-paracaspase inactivation in-
duces a lethal inflammatory syndrome with lympho-
cyte-dependent neurodegeneration in vivo. Paracas-
pase activity is essential for regulatory T cell (Treg)
and innate-like B cell development, but it is
largely dispensable for overcoming Malt1-depen-
dent thresholds for lymphocyte activation. In addi-
tion to NF-kB inhibitors, Malt1 cleaves an entire set
of mRNA stability regulators, including Roquin-1,
Roquin-2, and Regnase-1, and paracaspase inacti-
vation results in excessive interferon gamma (IFNg)
production by effector lymphocytes that drive
pathology. Together, our results reveal distinct
threshold and modulatory functions of Malt1 that1292 Cell Reports 9, 1292–1305, November 20, 2014 ª2014 The Autdifferentially control lymphocyte differentiation and
activation pathways and demonstrate that selective
paracaspase blockage skews systemic immunity
toward destructive autoinflammation.INTRODUCTION
Signals from antigen receptors (AgRs) control the development
and activation of T and B lymphocytes during adaptive immunity.
These pathways are essential for host defense against infec-
tions but can lead to immunodeficiency, autoimmunity, or cancer
when dysregulated. The pathway that activates NF-kB transcrip-
tion factors through the Card11, Bcl10, and Malt1 (CBM) protein
complex is a key regulator of lymphocyte signaling for T and B
cell differentiation and activation (Thome et al., 2010). Genetic
deletion of any of these factors results in severe deficits in the
development of regulatory T cells (Tregs), innate-like B1 B cells,
andmarginal zone B cells (Newton andDixit, 2003; Ruefli-Brasse
et al., 2003; Ruland et al., 2001, 2003). Moreover, although the
differentiation of conventional T and B cells is largely intact in
the absence of Card11/Bcl10/Malt1 signaling, all three factors
are essential for productive lymphocyte activation. Conse-
quently, loss-of-function mutations within the CBM complex
result in severe combined immunodeficiencies in humans andhors
in mice (Greil et al., 2013; Jabara et al., 2013; McKinnon et al.,
2014; Newton and Dixit, 2003; Ruefli-Brasse et al., 2003; Ruland
et al., 2001, 2003). On the other hand, gain-of-function alter-
ations of CBM signaling are recurrently detected in human
non-Hodgkin lymphoma, where they trigger constitutive NF-kB
activation, which is required for tumor cell survival (Staudt,
2010). These genomic aberrations include various independent
chromosomal translocations involving Bcl10 or Malt1 and onco-
genic mutations within Card11 in mucosa-associated lymphoid
tissue (MALT) lymphoma and in diffuse large B cell lymphoma
(Akagi et al., 1999; Lenz et al., 2008; Streubel et al., 2003; Willis
et al., 1999).
Malt1 is the essential effector molecule within the CBM com-
plex. This protein contains an amino-terminal death domain
and immunoglobulin-like domains for protein-protein interac-
tions and a proteolytically active paracaspase domain that
shares homology with caspases and metacaspases. In resting
lymphocytes, Malt1 is preassociated with Bcl10, and these two
molecules coassociate with Card11 upon signal induction after
T cell receptor (TCR) engagement or B cell receptor ligation
(Thome et al., 2010). Malt1 acts as a scaffold, recruiting protein
E3 ubiquitin ligases such as Traf6 to the newly formed CBM sig-
nalosome. This association leads to thenondegradingubiquitina-
tion of Bcl10, Traf6, and Malt1 itself and thereby activates IkB
kinase (IKK), which in turn promotes canonical NF-kB signaling
by phosphorylating inhibitory IkB proteins, thereby inducing their
degradation (Du¨wel et al., 2010). Malt1 further activates the JNK
and p38 kinases (Ruland et al., 2003), which regulate transcrip-
tion factors such as ATF2 (Gozdecka and Breitwieser, 2012).
The proteolytic domain ofMalt1, which has not beenwell defined
at thephysiological level, can cleave theA20andCYLDdeubiqui-
tinases that target K63-type polyubiquitin chains, and it can
negatively regulate NF-kB (Coornaert et al., 2008; Staal et al.,
2011). In addition, Malt1 cleaves the NF-kB family member
RelB, which also acts as an inhibitor of the canonical NF-kB
pathway in T cells (Hailfinger et al., 2011). Moreover, Malt1 has
recently been shown to cleave the endoribonuclease Regnase-
1 (Uehata et al., 2013), which regulates the stability of mRNAs.
Because Malt1 has nonredundant activating roles in AgR
signaling and possesses the only enzymatic activity within the
CBM complex, extensive pharmaceutical efforts to develop
Malt1 protease inhibitors for the treatment of prevalent chronic
and malignant immune-mediated diseases are being pursued
(Fonta´n andMelnick, 2013; Vucic andDixit, 2009). Indeed, selec-
tive inhibition of MALT1 protease activity via peptide or small-
molecule inhibitors is selectively toxic to human lymphoma cell
lines that exhibit aberrant CBM activity (Ferch et al., 2009; Nagel
et al., 2012). Moreover, because Malt1-deficient mice are
protected from autoimmune diseases such as experimental
autoimmune encephalomyelitis (Bru¨stle et al., 2012), it has
been speculated that pharmaceutical agents that block Malt1
paracaspase activity could inhibit chronic inflammatory reac-
tions in autoimmunity and would thus have the potential for
use as anti-inflammatory immunosuppressors. Despite these
endeavors, the physiological functions of Malt1 paracaspase
activity and the differential roles of the Malt1 scaffold versus its
proteolytic activity in lymphocyte development, activation, and
immune homeostasis are unknown.Cell ReWe report here that animals with a targeted Malt1 protease
inactivation develop fatal inflammation with neurodegeneration.
Although the paracaspase activity of Malt1 is largely dispensable
for overcoming the Malt1-controlled threshold for lymphocyte
activation, this activity is essential for the differentiation of lym-
phocytes including Tregs, marginal zone B cells, and B1 B cells.
In activated conventional T cells, Malt1 cleaves, in parallel with
NF-kB inhibitors, an entire set of mRNA stability factors that
includes Roquin-1 and Roquin-2 in addition to Regnase-1.
Also, Malt1 proteolytic inactivation results in excessive interferon
gamma (IFNg) production that mediates inflammatory pathol-
ogy. Our data demonstrate differential regulation of lymphocyte
differentiation and activation pathways by Malt1 and reveal
that Malt1 protease inhibition results in spontaneous lethal
autoinflammation.
RESULTS
Systemic Inflammation in the Absence of Malt1
Paracaspase Activity
To selectively inactivate Malt1 enzymatic activity in vivo, we re-
placed the active site cysteine within its protease domain with
alanine (C472A; Figures S1A and S1B). Mice with one or two
Malt1 paracaspase mutant (Malt1PM) alleles were viable and
born in Mendelian ratios similarly to Malt1-deficient (Malt1/)
animals (data not shown). Western blotting of splenic lysates
demonstrated that paracaspase mutant Malt1 protein expres-
sion in Malt1PM/ mice was comparable to Malt1 wild-type pro-
tein expression in Malt1+/ mice (Figure 1A). To assay catalytic
activity, we stimulated splenocytes with phorbol 12-myristate
13-acetate and ionomycin (PMA/Iono). Signal-induced cleavage
of the Malt1 substrate Ac-LRSR-AMC (Nagel et al., 2012)
was detected in activated splenocytes from Malt1+/ mice, but
not in those from Malt1/ or in Malt1PM/ animals (Figure 1B).
Thus, although the paracaspase mutant Malt1 protein was
expressed normally, it did not have proteolytic function.
Although Malt1/ mice are immunodeficient, the absence of
Malt1 does not affect animal growth or viability under homeo-
static conditions, andMalt1/ mice reach a normal age without
overt pathology (Ruefli-Brasse et al., 2003; Ruland et al., 2003).
In sharp contrast, the Malt1PM/ paracaspase mutant mice
failed to thrive and started to develop severe cachexia (Fig-
ure 1C) and lymphadenopathy with a strong increase in the
numbers of T and B cells (Figure 1D).Malt1PM/ mice developed
a systemic inflammatory disorder characterized by highly
elevated serum concentrations of the inflammatory cytokines
IFNg and tumor necrosis factor (TNF) already at an age of 6 to
10 weeks (Figure 1E), whereas serum cytokine levels of inter-
leukin 1b (IL-1b), IL-17, and IL-6 were not substantially elevated
inMalt1PM/ mice (Figure S2A). Of note, also Malt1PM/PM homo-
zygous paracaspase-deficient mice developed the same dis-
ease phenotype as observed for Malt1PM/ mice (Figures S2B
and S2D; data not shown). Importantly, Malt1PM/+ animals,
which carry only one mutated allele but additionally express
the proteolytic active Malt1 form, did not exhibit these pathol-
ogies (Figures S2B–S2D and data not shown), indicating that
the mutant protein does not behave as a dominant-negative
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Figure 1. Malt1 Protease Inactivation Results in Systemic Inflammation and Dysregulated Mucosal Immune Homeostasis
(A) Immunoblot of protein extracts from Malt1+/, Malt1/, and Malt1PM/ splenocytes for the detection of Malt1 and b-actin expression.
(B) LRSR-AMC cleavage assay with stimulated T cells from Malt1+/, Malt1/, and Malt1PM/ mice. The results are representative of three independent
experiments.
(C) Body weight curves for Malt1+/ and Malt1PM/ mice (n > 6 per time point, two-tailed unpaired t test).
(D) Photos displaying representative mesenteric (left) and cervical (right) lymph nodes fromMalt1+/mice andMalt1PM/mice at 8 weeks of age (scale bar, 1 cm).
The bar graph shows total numbers of B and T cells in the cervical lymph nodes fromMalt1+/ andMalt1PM/ mice at 8 to 10 weeks of age (right panel, mean ±
SEM, n = 4 each, two-tailed unpaired t test).
(legend continued on next page)
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We focused the further analysis on a comparison of the
Malt1PM/ mice with Malt1+/ and Malt1/ mice. Histological
analysis of theMalt1PM/ animals showed T andB cell organ infil-
tration. Mixed lymphocytic infiltrates were detected in the gastric
mucosa of Malt1PM/ mice (Figure 1F) with locally increased
inflammatory cytokine expression (Figure 1G). In vitro colon cul-
tures also showed spontaneous production of high IFNg, TNF,
and IL-1b levels in Malt1PM/, but not Malt1/ or Malt+/, sam-
ples (Figure 1H). In a model of inflammatory bowel disease, we
treated the animals with 3.5% dextran sodium sulfate (DSS) for
5 days to trigger intestinal epithelial damage (Oh et al., 2014).
Malt1PM/ mice developed a more rapid and aggravated
inflammatory disease compared to control mice, with severe
hemorrhagic diarrhea, increased weight loss (Figure 1I), and an
elevated histological severity score (Figures 1J and 1K).
Starting from 3 months of age, allMalt1PM/ mutant mice suf-
fered from a spontaneous neurological disorder with dystonia
and progressive ataxia (Figures 2A and 2B), indicative of a cere-
bellar defect. Rotarod analysis was used to quantitatively char-
acterize this motor-coordination deficit (Shiotsuki et al., 2010).
Whereas Malt1+/ and Malt1/ mice stayed on the rotating
rod for a minimum of 120 s, the Malt1PM/ animals failed to
accomplish this task even after numerous trials (Figure 2C; see
also Figure 2H). Loss of Purkinje cells is associated with severe
ataxic syndromes (Kullmann et al., 2012). Histopathological
analysis of the CNS indeed showed a marked reduction of Pur-
kinje cells in the cerebellar cortex ofMalt1PM/ mice (Figure 2D).
Notably, we also observed elevated numbers of CD4+ and CD8+
T lymphocytes in the brains ofMalt1PM/mice compared to con-
trol animals (Figure 2E). To determine the role of lymphocytes in
the systemic inflammation and neurodegeneration, we crossed
Malt1PM/ mice to Rag1-deficient animals, which lack T and B
cells. Moreover, we wanted to test whether disease in the para-
caspase mutants is caused by aberrant Malt1 signaling from
within canonical Bcl10/Malt1 complexes or whether the catalyt-
ically inactive Malt1 protein mediates its pathological effects via
Bcl10-independent mechanisms. Thus, we also crossed the
Malt1PM allele into a Bcl10-deficient background. The absence
of Bcl10 prevented both systemic inflammation and ataxia (Fig-
ures 2F and 2G), and the lack of lymphocytes in the Rag1/
background also completely rescued Malt1PM/ mice from dis-
ease, normalized the levels of inflammatory cytokines in the
blood (Figure 2F), and prevented the development of neurolog-
ical defects as determined by clinical ataxia scoring (Figure 2G)
and rotarod analysis (Figure 2H). Altogether, these in vivo obser-(E) Serum concentrations of IFNg and TNF were measured forMalt1+/ (n = 6),Ma
indicate the mean ± SEM (two-tailed unpaired t test).
(F) Representative histologies of hematoxylin and eosin (H&E)-stained stomachs f
infiltration in Malt1PM/ mice. Scale bars indicate 100 mm.
(G) Real-time PCR analysis of reverse-transcribed RNA obtained from stomach t
relative IFNg and TNF transcript levels (mean ± SEM, n = 4 each, two-tailed unp
(H) Colon tissue samples from untreated Malt1+/, Malt1PM/, and Malt1/ mice
IFNg, TNF, and IL-1b were measured by cytometric bead array. Horizontal bars
(I) Bodyweight curves ofMalt1+/,Malt1PM/, andMalt1/mice during DSS treat
SEM; starting with six to eight animals per group, two-tailed unpaired t test).
(J) Representative H&E-stained colon tissue sections from Malt1+/ and Malt1PM
(K) Severity score of DSS-induced colitis inMalt1+/ (n = 8) andMalt1PM/mice (n
Mann-Whitney test. *p < 0.05.
Cell Revations reveal a counterintuitive autoinflammatory condition and
neuropathology upon selective Malt1 paracaspase inactivation.
Moreover, the results indicate that these disorders are caused
by aberrant Malt1 function within Bcl10-containing complexes,
and they prove genetically that the pathology in Malt1 paracas-
pase mutant mice is dependent on aberrant lymphocyte activity.
Differential Control of Lymphocyte Differentiation and
Activation Signals
Because of the findings above, we next studied lymphocyte dif-
ferentiation and activation in Malt1PM/ mice prior to the onset
of cachexia. Flow cytometric analysis of T cell differentiation in
the thymi of Malt1PM/ mice revealed normal numbers and fre-
quencies of double-negative, double-positive, and CD4 or CD8
single-positive T cells similar to those in Malt1-deficient mice
(Ruefli-Brasse et al., 2003; Ruland et al., 2003), indicating normal
thymic T cell differentiation (Figure 3A). However, Malt1PM/
mice almost completely lacked CD4+CD25+Foxp3+ thymic
regulatory T cells, similarly to Malt1/ mice (Figure 3B).
Early B cell development in the bone marrow was not affected
inMalt1PM/mice, as theseanimals exhibitednormaldistributions
of pre/pro B cells (B220lowIgM), immature B cells (B220lowIgM+),
and recirculatingBcells (B220highIgM+) (Figure3C).Neither the to-
tal number of peripheral B cells nor the frequencies of immature
(B220+IgM+IgD) or mature (B220+IgMIgD+) B2 B cells differed
among the Malt1+/, Malt1PM/, and Malt1/ mice (data not
shown). However, the B220+CD21highCD23low splenic marginal
B cell population was almost completely absent in Malt1PM/
mice (Figure 3D), and the frequency of peritoneal B1 B cells
(CD19+B220low) (Figure 3E) was also severely reduced in
Malt1PM/mice, similar to the results observed inMalt1-deficient
mice (Ruefli-Brasse et al., 2003; Ruland et al., 2003). Thus, the
Malt1-dependent signals for Treg development and innate-like
marginal zone and B1 B cell generation are strictly dependent
on Malt1 proteolytic activity.
We further detected significant increases in the percentages
of CD8+ memory T cells (CD62L+CD44+) and CD4+ and CD8+
effector memory T cells (CD62LCD44+) in the spleens of
Malt1PM/ animals when compared to those from eitherMalt1+/
orMalt1/ mice, whereas the pool of naive T cells was reduced
in Malt1PM/ animals (Figure 4A). Because memory and effector
memory cells arise from naive T cells after activation, these data
suggest that a substantial proportion of conventional Malt1PM/
T cells might have received a productive TCR signal in vivo. To
directly test the paracaspase function in T cell activation, welt1/ (n = 3), andMalt1PM/ (n = 5) mice at 6 to 8 weeks of age. Horizontal bars
romMalt1+/ andMalt1PM/ littermates at 16 weeks demonstrating lymphocyte
issue samples of Malt1+/ and Malt1PM/ mice at 16 weeks. Bars indicate the
aired t test).
at an age of 12 weeks were cultured for 48 hr, and cytokine concentrations of
indicate the mean ± SEM (n = 3–4, two-tailed unpaired t test).
ment. The data show the percentages of initial weight prior to treatment (mean ±
/ mice after DSS treatment. Scale bars indicate 200 mm.
= 6) by evaluation of colon histology. Horizontal bars indicate the mean ± SEM,
ports 9, 1292–1305, November 20, 2014 ª2014 The Authors 1295
Figure 2. Lymphocyte-Dependent Systemic Inflammation and Neurodegeneration in Paracaspase Mutant Mice
(A) Hindlimb clasping as observed for a representative Malt1PM/ mouse compared to a Malt1+/ control.
(B) Ataxia severity scores forMalt1+/ (n = 10),Malt1PM/ (n = 10), andMalt1/mice (n = 5) at an age between 3 and 6months. Horizontal bars indicate themean ±
SEM, Mann-Whitney test.
(C) The motor coordination ofMalt1+/ andMalt1PM/mice was tested in a rotarod experiment with ten consecutive trials at 4 to 5 months of age. The data show
the mean duration of the trials (mean ± SEM; n = 4 each, two-tailed unpaired t test).
(D) Cerebellar section from representative atacticMalt1PM/ mice and age-matched (>20 weeks)Malt1+/ and Malt1/ control animals were stained with anti-
calbindin in order to visualize Purkinje cells (arrow). Scale bars indicate 100 mm.
(E) Absolute numbers of CD4+ and CD8+ T lymphocytes in the brains ofMalt1+/ andMalt1PM/mice at an age of 4–5 months were determined by flow cytometry
(mean ± SEM; n = 3 each, two-tailed unpaired t test).
(F) IFNg, TNF, and IL-1b levels in the serum of Malt1+/, Malt1PM/, Malt1PM/;Bcl10/, and Malt1PM/;Rag1/ mice at 3–4 months of age. Horizontal bars
indicate the mean ± SEM (n = 3–6, two-tailed unpaired t test).
(G) Ataxia scoring of Malt1+/ (n = 3), Malt1PM/ (n = 5), Malt1PM/;Bcl10/ (n = 3), and Malt1PM/;Rag1/ mice (n = 7) at an age between 7 and 9 months.
Horizontal bars indicate the mean ± SEM, Mann-Whitney test.
(H) The motor coordination of composite Malt1PM/, Rag1/ (n = 4), and Malt1/ mice (n = 3) was tested at an age of 4–5 months in the same set of rotarod
experiments as shown in (C). The data show the mean duration of the trials (mean ± SEM).
*p < 0.05.
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Figure 3. Paracaspase Activity Controls Treg and Innate B Cell Development
(A) Flow cytometry of thymic T cell populations ofMalt1+/ (n = 10),Malt1PM/ (n = 8), andMalt1/ mice (n = 6) characterized by surface CD4 and CD8 staining.
(B) Thymus-derived regulatory T cells ofMalt1+/ (n = 10),Malt1PM/ (n = 8), andMalt1/ mice (n = 6) were measured by flow cytometry after extracellular CD4
and CD25 staining and intracellular Foxp3 staining.
(C) Flow cytometry of pre/pro-B cells (B220 low, IgM), immature B cells (B220 low, IgM+), and recirculating B cells (B220 high, IgM+) in the bone marrow of
Malt1+/ (n = 9), Malt1PM/ (n = 7), and Malt1/ mice (n = 5).
(D) Flow cytometry of marginal zone B cells (CD21+CD23) in spleens of Malt1+/, Malt1PM/, and Malt1/ mice (n = 4 each).
(E) Flow cytometry of peritoneal B1 cells (CD19+B220lo) inMalt1+/ (n = 6),Malt1PM/ (n = 5), andMalt1/mice (n = 5). The dot plot graphs display representative
flow cytometry results, and bar graphs show the mean ± SEM (two-tailed unpaired t test).
All analyses were performed with animals at 8 to 10 weeks of age. *p < 0.05; ns, not significant.
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Figure 4. Paracaspase Activity Is Largely
Dispensable for Malt1-Mediated Lympho-
cyte Activation
(A) Flow cytometry of naive (CD62L+CD44),
memory (CD62L+CD44+), and effector/memory
T cells (CD62LCD44+) in spleens of Malt1+/
(n = 11),Malt1PM/ (n = 9), andMalt1/mice (n =
6) within the CD4+ (left) and CD8+ (right) subsets.
The bar graphs show the mean ± SEM (two-tailed
unpaired t test).
(B) Viability of purified CD4+ T cells fromMalt1+/,
Malt1/, and Malt1PM/ mice (n = 4 each)
cultured in vitro either unstimulated (left) or stim-
ulated with anti-CD3/CD28 (right). At the indi-
cated time points, the percentage of living cells
was determined by Annexin V/7-AAD staining in
flow cytometry (mean ± SEM, two-tailed unpaired
t test).
(C) Cell division of isolated CD4+ T cells from
Malt1+/, Malt1PM/, and Malt1/ mice investi-
gated by carboxyfluorescein succinimidyl ester
(CFSE) flow cytometry after stimulation with
plate-bound anti-CD3/CD28 for 72 hr. The data
are representative of three experiments.
(D) Flow cytometry of CD25 activation marker
expression in naive T cells of the respective ge-
notypes after 18 hr of stimulation with anti-CD3/
CD28. Red lines indicate median values in the
Malt1+/ T cells after stimulation. The data are
representative of three experiments.
(E) IgG1 immunoglobulin levels in the sera of
Malt1+/ (n = 18),Malt1PM/ (n = 15), andMalt1/
mice (n = 9) after NP-OVA immunization
measured by NP-specific ELISA. Sera were
collected at the indicated time points after im-
munization. The data are shown in a logarithmic
scale with horizontal bars indicating the means
(two-tailed unpaired t test).
All analyses were performed with animals at 8 to
10 weeks of age. *p < 0.05; ns, not significant.purified naive T lymphocytes from Malt1+/, Malt1PM/, and
Malt1/ animals and stimulated these via their AgR in vitro.
Compared to the wild-type, both Malt1PM/ and Malt1/ CD4+
T cells showed slightly reduced viability after 2 days of stimula-
tion in vitro (Figure 4B). However, whereas the survivingMalt1/
T cells exhibited severely impaired TCR-induced proliferation
as expected (Ruefli-Brasse et al., 2003; Ruland et al., 2003),
Malt1PM/ T cells divided vigorously, although their proliferation
rate was suboptimal when compared to Malt1+/ T cells (Fig-
ure 4C). Moreover, in contrast to the complete Malt1 deletion,
paracaspase inactivation failed to affect the upregulation of the
activation marker CD25 (Figure 4D).
Next, we immunized the animals with (4-hydroxy-3-nitro-
phenyl)acetyl-ovalbumin (NP-OVA) to study antigen-specific
lymphocyte activation in vivo. Again, as expected, the T cell-
dependent production of NP-specific immunoglobulin G1
(IgG1) antibodies was defective in Malt1/ mice (Figure 4E)1298 Cell Reports 9, 1292–1305, November 20, 2014 ª2014 The Authors(Ruefli-Brasse et al., 2003; Ruland
et al., 2003). However, Malt1PM/ mice
produced normal amounts of antigen-
specific IgG1 2weeks after immunization,although their adaptive immune response was delayed (Fig-
ure 4E). Together, these data demonstrate that the paracaspase
activity of Malt1 is, to a considerable extent, dispensable for
Malt1-controlled lymphocyte activation pathways in vitro and
in vivo.
Threshold and Modulatory Activity of Malt1 in TCR
Signaling
We next isolated naive CD4+ T cells for biochemical analysis. As
previously shown, Malt1 ablation blocks PMA/Iono-induced and
anti-CD3/anti-CD28-induced IKK activation (Figures 5A and 5D),
and the MAP kinases p38 and Jnk were also not activated
in Malt1/ T cells despite normal Erk signaling (Figure 5B)
(Ruefli-Brasse et al., 2003; Ruland et al., 2003). In contrast, the
selective paracaspase mutation did not impair IKK, p38, or Jnk
activation (Figures 5A and 5B). Consistently, IkBa was phos-
phorylated and degraded normally (Figures 5A and 5D), and
Figure 5. Threshold and Modulatory Activ-
ity of Malt1 in TCR Signaling
(A) Purified naive CD4+ T cells from Malt1+/,
Malt1/, and Malt1PM/ mice were stimulated for
the indicated time points with PMA and ionomycin
and analyzed by western blot with antibodies
against Malt1, phospho-IKKa/b, phospho-IkBa,
IkBa, and b-actin as a loading control. The
results are representative of three independent
experiments.
(B) To test MAP kinase signaling, the same ex-
tracts as used in (A) were analyzed by immunoblot
using antibodies to phospho-p38, phospho-Jnk,
and phospho-Erk.
(C) CD4+ T cells from Malt1+/, Malt1PM/,
and Malt1/ mice were stimulated with PMA
and ionomycin for the indicated time points.
Cell lysates were analyzed by western blot
with antibodies against phospho-Atf-2 and anti-
b-actin.
(D) Purified CD4+ T cells from Malt1+/, Malt1/,
and Malt1PM/ mice were stimulated for the
indicated time points with plate-bound anti-
CD3 (5 mg/ml) and soluble anti-CD28 (2 mg/ml)
in the presence of cycloheximide (10 mg/ml)
and analyzed by western blot with antibodies
against Malt1, phospho-IKKa/b, IkBa, and
b-actin.
(E) CD4+ T cells from Malt1+/, Malt1PM/, and
Malt1/ mice were stimulated with plate-bound
anti-CD3 (5 mg/ml) and soluble anti-CD28
(2 mg/ml) for the indicated time points in the
presence of the proteasome inhibitor MG132
(10 mg/ml). Cell lysates were analyzed by
immunoblot using antibodies specific for RelB,
Cyld, and b-actin.
(F) CD4+ T cells were left unstimulated or were
stimulated for 8 hr by plate-bound anti-CD3 and
anti-CD28. The DNA binding activity of the nu-
clear extracts was analyzed by an electrophoretic
mobility shift assay using oligos with NF-kB
binding sites or NF-Y binding sites as a control.
(G) Naive CD4+ T cells were treated as in (F). Nu-
clear extracts were prepared and DNA binding
activities of specific NF-kB subunits were quanti-
fied by an ELISA-based assay. For each subunit,
the data from three experiments were normalized to Malt1+/ control T cells and are expressed as the mean ± SEM (two-tailed unpaired t test).
(H) CD4+ T cells from Malt1+/, Malt1PM/, and Malt1/ mice were stimulated as in (E). Cell lysates were analyzed by immunoblot using antibodies specific for
Malt1, Roquin1/2, Regnase1, and Gapdh.
All analyses were performed with animals at 8 to 10 weeks of age. *p < 0.05.the transcription factor Atf2 was also phosphorylated normally in
Malt1PM/ T cells, but not in Malt1-deficient T cells (Figure 5C).
Next, we investigated the cleavage of candidate Malt1 sub-
strates in primary Malt1PM/ T cells stimulated with anti-CD3/
anti-CD28 or with PMA/Iono. Robust signal-induced proteolysis
of RelB and Cyld was observed in T cells from Malt1+/ mice,
but not in T cells from Malt1/ or Malt1PM/ mice (Figures 5E
and S3A). Due to the lack of an antibody that recognizes cleaved
murine A20, we were unable to study endogenous A20 process-
ing. Because these Malt1 targets can negatively regulate canon-
ical NF-kB activity (Hailfinger et al., 2011; Reiley et al., 2007), we
measured NF-kB DNA binding 8 hr after T cell stimulation. Elec-
tromobility shift assays revealed suboptimal NF-kB DNA bindingCell ReinMalt1PM/ T cells (Figure 5F). In linewith the defective cleavage
of RelB (Figure 5E), stimulated T cells from Malt1PM/ mice
showed increased amounts of nuclear RelB DNA-binding
compared to Malt1+/ T cells (Figure 5G). Moreover, the DNA-
binding activities of c-Rel and p50 were significantly reduced
in Malt1PM/ mice, whereas p65 DNA binding was not affected
by mutation of the paracaspase (Figure 5G). Thus, the paracas-
pase activity of Malt1 fine-tunes canonical NF-kB activity after
initial IKK activation and particularly controls the full nuclear
DNA binding of the NF-kB subunits p50 and c-Rel.
Immune-modulatory gene expression is not only controlled
by transcription factors but also strongly regulated at the level
of mRNA stability (Cheadle et al., 2005; Vogel et al., 2013).ports 9, 1292–1305, November 20, 2014 ª2014 The Authors 1299
Figure 6. mRNA Expression and IFNg Production in Malt1 Mutant T Cells
(A) FACS-sorted naive CD4+CD62L+CD25 T cells fromMalt1+/,Malt1PM/, andMalt1/mice (n = 4 each) were left unstimulated or were stimulated for 4 hr with
anti-CD3 and anti-CD28. Total RNA was isolated, and gene expression profiling was performed. The microarray data were analyzed for the expression of NF-kB
target genes that were >2-fold upregulated upon TCR stimulation in at least one of the three genotypes. The upregulated genes could be classified into four
(legend continued on next page)
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Regnase-1 was recently identified as aMalt1 substrate that con-
trols mRNA stability (Uehata et al., 2013), and we discovered
independently that Malt1 can cleave the RNA-binding proteins
Roquin-1 and Roquin-2 (Jeltsch et al., 2014). Similar to Reg-
nase-1, the Roquin paralogs bind to stem-loop structures in
the 30 UTRs of target mRNAs to control their decay (Leppek
et al., 2013). To define the requirement for Malt1 proteolysis of
Regnase-1 and Roquin degradation, we performed western
blots using either an anti-Regnase-1 antibody or a monoclonal
antibody that recognizes a conserved N-terminal epitope in
Roquin-1 and Roquin-2 using lysates from activated T cells.
The Roquin proteins were completely degraded in stimulated
wild-type T cells, and the proteolysis of the Roquins was strictly
dependent on Malt1 proteolytic activity (Figures 5H and S3B).
Moreover, Regnase-1 cleavage was observed in wild-type
T cells but was abolished in Malt1PM/ T cells, similar to the
results in Malt1/ T cells (Figures 5H and S3C).
Malt1 Protease Activity Prevents Pathological
Overproduction of IFNg
The simultaneous functions of Malt1-mediated proteolysis in
signal-dependent NF-kB control and the cleavage of mRNA
decay factors prompted us to investigate the overall impact of
the paracaspase mutation on TCR-induced mRNA expression.
To this end, we fluorescence-activated cell sorting (FACS)-
purified naive (CD4+CD62L+CD25) T cells from Malt1+/,
Malt1PM/, and Malt1/ mice, stimulated these cells via the
TCR, and performed microarray mRNA expression analysis.
First, we focused onNF-kB target mRNAs (as defined in the Sup-
plemental Experimental Procedures) that were at least 2-fold
upregulated in at least one of the three genotypes. Statistical
criteria subdivided these mRNAs into qualitatively distinct
groups (Figure 6A). The first group includes mRNAs such as
the c-Rel target Bcl2l1 that were robustly upregulated inMalt1+/
cells and not upregulated or significantly less so inMalt1PM/ and
Malt1/ T cells. The second includes NF-kB targets such as IL-2groups as described in the main text. Expression of three representative genes p
(mean ± SD, two-tailed unpaired t test).
(B) Real-time PCR analysis of IFNg transcript levels in naive T cells of the given gen
representative results from at least three independent experiments (mean ± SD,
(C) CD4+ T cells from Malt1+/ (black line, circles), Malt1PM/ (dashed line, squa
ionomycin for 4 hr, actinomycin Dwas added to blockmRNA synthesis, and IFNg t
and normalized to b-actin message (n = 4–5, mean ± SEM, two-tailed unpaired t te
asterisks for Malt1/ versus Malt1+/).
(D) IFNg protein levels measured by ELISA in supernatants of naive T cells ofMalt
with plate-bound anti-CD3/anti-CD28 for 18 hr (mean ± SEM, two-tailed unpaire
(E) Evaluation of the gene expression profiling experiment as described in (A) s
Malt1/, T cells compared with the Malt1+/ T cells.
(F) Ataxia scoring ofMalt1PM/ (n = 10) andMalt1PM/; Ifng/mice (n = 5). The m
animals (mean ± SEM, Mann-Whitney test).
(G) Cells from cervical lymph nodes of Malt1+/, Malt1PM/, and Malt1PM/;IFN
analyzed by flow cytometry. The bar graph shows total numbers of B and T cells
(H) TNF levels in the serum ofMalt1+/ (n = 7),Malt1PM/ (n = 7), andMalt1PM/;IFN
unpaired t test).
(I) Body weights for female and male Malt1+/, Malt1PM/, and Malt1PM/;I
t test).
(J) Histopathological inflammation scores of gastric antrum tissue samples fromM
of age. Horizontal bars indicate the mean ± SEM (Mann-Whitney test). If not stated
0.05; ns, not significant.
Cell Rereceptor-alpha (CD25) that were comparably upregulated in
Malt1+/ and Malt1PM/ T cells but significantly less so in
Malt1/ T cells. The third group includes mRNAs such as NF-
kB2 that were upregulated similarly in all three genotypes. The
findings are in principle in line with differential control of the
NF-kB response via Malt1’s scaffold and protease functions.
Surprisingly, we also identified a fourth group of NF-kB-regu-
lated genes, including the inflammatory cytokine IFNg, that show
much higher mRNA expression in stimulated Malt1PM/ T cells
compared to either Malt1+/ or Malt1/ T cells (Figure 6A).
Because we initially observed that Malt1PM/ animals develop
spontaneous systemic inflammation with pathological IFNg
levels in vivo, we investigated IFNg production after T cell activa-
tion in more detail. Increased IFNgmRNA levels were confirmed
by RT-PCR analysis in stimulated Malt1PM/ T cells in compari-
son to Malt1+/ and Malt1/ T cells (Figure 6B). The inhibition
of RNA synthesis by actinomycin D further revealed an increased
half-life of IFNg mRNA in Malt1PM/ T cells and in Malt1/
T cells, indicating that IFNg mRNA stability is controlled by
Malt1 (Figure 6C). Consistent with the enhanced total IFNg
mRNA expression levels in Malt1PM/ T cells, we also detected
higher IFNg protein production in Malt1PM/ T cells compared
to bothMalt1+/ and Malt1/ T cells (Figure 6D). Finally, by ex-
tending the microarray analysis of stimulated T cells to global
mRNA expression analysis, we observed high expression of
interferon-stimulated genes specifically in Malt1PM/ T cells but
not Malt1/ T cells, demonstrating that interferon signaling
is strongly activated in Malt1PM/ T cells (Figure 6E). To define
the in vivo role of dysregulated IFNg expression in Malt1PM/
mice, we crossed the Malt1PM allele into an IFNg-deficient back-
ground. Intriguingly, whereas nine out of ten Malt1PM/ litter-
mates in an IFNg+/+ or IFNg+/ background had to be euthanized
within 20 weeks of birth because they developed the neuropa-
thology described above, the absence of IFNg rescued the
Malt1PM/ mice from neuropathology (Figure 6F), although
lymphadenopathy was still present in these animals (Figure 6G).er group is shown, each obtained from four biological replicates per genotype
otypes after in vitro stimulationwith anti-CD3/anti-CD28 for 4 hr. The data show
two-tailed unpaired t test).
res), and Malt1/ (dotted line, triangles) mice were stimulated with PMA and
ranscript levels weremeasured by quantitative PCR at the indicated time points
st results are indicated by gray asterisks forMalt1PM/ versusMalt1+/ or black
1+/ (n = 4),Malt1PM/ (n = 4), andMalt1/mice (n = 3) after in vitro stimulation
d t test).
howing higher expression of interferon-regulated genes in Malt1PM/, but not
ice were 20 weeks of age or younger in the case of moribund atacticMalt1PM/
g/ mice at 20 weeks of age were stained for lymphocyte populations and
(n = 4, mean ± SEM).
g/mice (n = 8) at an age between 11 and 15 weeks (mean ± SEM, two-tailed
FNg/ mice at 14–15 weeks of age (mean ± SEM, two-tailed unpaired
alt1+/ (n = 7),Malt1PM/ (n = 6), andMalt1PM/;IFNg/mice (n = 5) at 20weeks
otherwise, analyses were performed with animals at 8 to 10 weeks of age. *p <
ports 9, 1292–1305, November 20, 2014 ª2014 The Authors 1301
Measurement of inflammatory cytokine concentrations in their
serum revealed that the absence of IFNg led to a significant
reduction of TNF concentrations (Figure 6H), and Malt1PM/;
IFNg/ animals also failed to develop cachexia (Figure 6I).
Moreover, the inflammatory activity in the gastric mucosa
in Malt1PM/;IFNg/ mice was also significantly reduced
compared to that inMalt1PM/ mice (Figure 6J). Together, these
data demonstrate that IFNg is a key driver of the systemic inflam-
matory disorder in paracaspase mutant mice.
DISCUSSION
Together, our genetic results identify distinct molecular and
cellular functions of Malt1 that act in concert to maintain tissue
homeostasis. Together with previously published work, we pro-
pose the following model: the Malt1 scaffold sets a threshold for
antigen receptor signaling to activate IKK, Jnk, and p38 for proin-
flammatory gene transcription. The proteolytic activity of Malt1
has a subsequent dual modulatory role: it degrades a series of
negative NF-kB regulators to enforce transcription of a subset
of immune response genes, and it inactivates an entire class of
mRNA-binding proteins that directly control mRNA decay.
Thus, both transcriptional activity and mRNA stability, which in
combination are highly important for the balanced expression
of immune regulatory factors (Ivanov and Anderson, 2013; Villar-
ino et al., 2011), are intimately controlled by the Malt1 protease.
These mechanisms differentially control lymphocyte differentia-
tion and activation.
Comparable to a complete Malt1 deletion, the selective inac-
tivation of Malt1 proteolytic activity prevents the development
of anti-inflammatory thymus-derived Tregs and of marginal
zone and B1 B cells. Although mRNA stability pathways can
contribute to developmental lymphocyte fate decisions, the
development of these specific T- and B cell lineages is particu-
larly sensitive to perturbations in NF-kB activity (Gerondakis
and Siebenlist, 2010). In particular, c-Rel activity is required for
regulatory T cell lineage commitment (Ruan et al., 2009).
Because the Malt1 protease mediates full NF-kB and c-Rel
activation, we hypothesize that such signals are important for
the differentiation and/or maintenance of Tregs, marginal zone
and B1 B cells.
In contrast to its vital function in lymphocyte development, the
paracaspase activity of Malt1 is to a considerable extent
dispensable for its mediation of lymphocyte activation. In vitro,
T cell signaling induces normal IKK, Jnk, and p38 activation as
well as p65DNAbinding and Atf2 phosphorylation, and activated
Malt1PM/ T cells expand almost as robustly as wild-type T cells.
In vivo, the pure Malt1 scaffold is also sufficient to overcome
the threshold for productive lymphocyte activation, as demon-
strated by the ability ofMalt1PM/mice to mount robust adaptive
immune responses after T cell-dependent antigen challenge
in contrast toMalt1/ animals. However, without Malt1-depen-
dent proteolysis, lymphocyte activity is not appropriately coun-
terbalanced. This can in part be explained by the developmental
defects in the Treg lineage, because Tregs are required to pre-
vent lethal multiorgan autoimmune inflammation. Such pathol-
ogies occur in the IPEX syndrome, which is caused by a naturally
occurring Foxp3 mutation in humans resulting in Treg defi-1302 Cell Reports 9, 1292–1305, November 20, 2014 ª2014 The Autciencies, as well as upon targeted Foxp3 gene inactivation or af-
ter toxin-mediated depletion of Tregs in mice (Bacchetta et al.,
2006; Kim et al., 2007). Thus, insufficient Treg-dependent sup-
pression of Malt1PM/ effector T cells likely supports the patho-
logical accumulation of lymphocytes in paracaspase mutant
mice that infiltrate mucosal tissue and drive lethal autoimmune
inflammation. Intriguingly, we also observed lymphocyte-depen-
dent degeneration of Purkinje cells in paracaspase mutant mice
resulting in a severe cerebellar ataxic syndrome. Although
the exact pathomechanism that provokes this neurodegenera-
tive disease remains to be determined, the disorder shares
histopathological characteristics with paraneoplastic cerebellar
degeneration in human Hodgkin and non-Hodgkin lymphoma,
wherein a loss of Purkinje cells is also mediated by aberrant
lymphocyte activity (Briani et al., 2011; Darnell, 2004). The
inability of lymphocytes that completely lack Malt1 to overcome
the initial threshold for activation can explain why these immune-
mediated pathologies are observed inMalt1PM/mice, but not in
Malt1/ mice.
After activation of conventional T cells, Malt1 not only regu-
lates the NF-kB pathway but also cleaves Roquin-1, Roquin-2,
and Regnase-1, which fine-tune the expression of a vast set of
target mRNAs, particularly ones that have highly dynamic
expression that needs to be altered rapidly during immune re-
sponses (Akira, 2013; Jeltsch et al., 2014), and during helper
T cell differentiation, Roquin and Regnase-1 cooperate in the
repression of shared target mRNAs (Jeltsch et al., 2014). Condi-
tional gene targeting of the individual factors in T cells has shown
that Roquin-1, Roquin-2, and Regnase-1 are all required for the
maintenance of immune homeostasis (Uehata et al., 2013; Vogel
et al., 2013). Transgenic T cell-specific overexpression of
Roquin-1 has also been linked to inflammatory responses via
enhanced production of IFNg and other inflammatory cytokines
(Ji et al., 2012; Kim et al., 2012). Germline mutations in Roquin-1
that generate hypomorphic Roquin-1 (san) alleles also induce an
accumulation of pathological effector T cells with excessive pro-
duction of IFNg due to a breakdown in IFNg mRNA repression
(Chang et al., 2012; Lee et al., 2012; Vinuesa et al., 2005).
Thus, nonphysiological levels and activity of Roquin proteins
have previously been associated with exacerbated IFNg produc-
tion, although the exact molecular mechanisms for this effect
have remained unclear. Roquin-1, Roquin-2, and Regnase-1
bind to stem loop motifs of multiple target mRNAs (Akira,
2013), and bioinformatic analysis has estimated that more than
50%of the total transcriptomic changes that are detected during
T cell activation are directly regulated at the level of mRNA
stability (Cheadle et al., 2005). In addition, Regnase-1 controls
gene transcription by directly counteracting the endonuclease
Dicer during pre-microRNA processing (Suzuki et al., 2011),
and Roquins can also function as degradative ubiquitin ligases
for signaling proteins under certain conditions (Maruyama
et al., 2014). Thus, in activatedMalt1PM/ T cells, multiple factors
that are primarily controlled by NF-kB, Regnase-1, and Roquin-1
and Roquin-2 are dysregulated and additional genes are
assumed to be up- or downregulated secondarily to the primary
factors. We observed that the stability of the Regnase-1 and Ro-
quin targets IL-2 and Ox40, but not that of Icos or c-Rel, is dimin-
ished in Malt1PM/ T cells (data not shown) (Uehata et al., 2013;hors
Vogel et al., 2013). This overall complexity indicates that more
than a single linear pathway is likely responsible for the initiation
and perpetuation of the pathological activities ofMalt1PM/ lym-
phocytes, and future studies are required to dissect these path-
ways. Nevertheless, as the final consequence of paracaspase in-
hibition, we detected excessive IFNg generation in vivo, and the
ability of an IFNg/ background to rescue paracaspase mutant
animals from cachexia and neurodegeneration established
excessive IFNg production as a mechanism of the pathology.
Malt1 was originally identified from a chromosomal transloca-
tion breakpoint inMALT lymphoma (Dierlammet al., 1999). Inten-
sive research over more than a decade has identified Malt1 as a
major activator of adaptive immunity that can drive normal and
malignant lymphocyte proliferation and survival. The overarching
paradigm presumes that Malt1 paracaspase inhibition would be
immunosuppressive. We report here that Malt1 not only induces
and amplifies immune-activating signals but also antagonizes
inflammation through its proteolytic activity, which controls
regulatory T cell development and intrinsic effector cell pathways
of transcription and posttranscriptional regulation. Thus, the
distinct threshold andmodulatory functions withinMalt1 balance
pro- and anti-inflammatory immunity. The net outcome of selec-
tive paracaspase inactivation in vivo is an imbalance of the
immune system that results in lethal lymphocyte- and IFNg-
mediated inflammation. These surprising results cast some
concern on the idea of chronically and systemically inhibiting
Malt1 proteolytic activity for therapeutic purposes in humans.
EXPERIMENTAL PROCEDURES
Ethics Statement
All animal work was conducted in accordance with German Federal Animal
Protection Laws and approved by the Institutional Animal Care and Use
Committee at the Technical University of Munich.
Malt1 Paracaspase Enzymatic Assay
Lymphocytes were isolated from spleen and lymph nodes, and 8 3 107 cells
were left unstimulated or were stimulated for 30 min at 37C with 200 nM
PMA plus 500 nM ionomycin. The assay was performed as described
previously (Nagel et al., 2012).
Serum Cytokine Detection
ELISA was performed using the Mouse IFNg OptEIA Kit (#555138, BD Biosci-
ences). For detection of serum cytokine concentrations, the Enhanced Sensi-
tivity CBA kit (BD Biosciences) was applied for the respective cytokines.
Neurophenotyping
Ataxia was scored according to a composite phenotyping system including
hindlimb clasping, ledge test, gait, and kyphosis as described previously
(Guyenet et al., 2010). For rotarod analysis, themicewere tested in ten consec-
utive trials with 60 s intertrial intervals at constant speed (25 rpm) for a
maximum of 120 s per trial on a mouse rotarod (Ugo Basile).
Purification and Stimulation of T Cells
Total T cells were purified by negative selection using magnetic beads (Dynal,
Invitrogen) against B cells (B220) andmyeloid cells (CD11b). CD4+ T cells were
purified using MACS CD4+ or CD4+CD62L+ T Cell isolation kits (Miltenyi). For
cleavage experiments, cells were pretreated with 10 mg/ml MG132 for 20 min
at 37C in medium. Cells were stimulated with PMA (100 nM, Adipogen) and
ionomycin (250 nM, Alexis) or with plate-bound anti-CD3 (50 or 5,000 ng/ml,
145-2C11) and anti-CD28 (2 mg/ml, 37.51, both from eBioscience) antibodies
after precoating with anti-Syrian hamster antibodies (10 mg/ml, F[ab0]2 frag-Cell Rement of IgG H+L, rabbit, Jackson ImmunoResearch) in RPMI 1640 medium
supplemented with 5% fetal bovine serum (v/v), penicillin (100 U/ml)/strepto-
mycin (100 mg/ml), L-glutamine (2 mM), and 2-mercaptoethanol (50 mM, all
Gibco) for the indicated time points at 37C.
Statistics
Statistical analysis was performed using GraphPad Prism (GraphPad Soft-
ware) and Microsoft Excel. In general, groups were compared using unpaired
two-tailed t tests assuming normal distributions and unequal variances or un-
paired two-tailed Mann-Whitney tests as indicated in the figure legends.
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